Sobr Safe, Inc. (SOBR) Stock Price & Analysis
Sobr Safe, Inc. (SOBR) rose 1.78% to USD 0.43 as of September 8, 2026 at 09:36 UTC, according to Nexqual real-time market data.
SOBR last closed at USD 0.43; the session ranged USD 0.42–0.45 on volume of 101,261 shares. Market capitalization is —, with a 52-week range of USD 0.35–3.97 (NCM). Source: Nexqual, September 8, 2026 at 09:36 UTC.
Key Statistics (as of September 8, 2026 at 09:36 UTC)
| Price | USD 0.43 |
|---|---|
| Change | ▲ 1.78% (up) |
| Previous Close | USD 0.43 |
| Open | USD 0.43 |
| Day Range | USD 0.42 – 0.45 |
| 52-Week Range | USD 0.35 – 3.97 |
| Volume | 101,261 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (SOBR)
Nexqual's technical model rates SOBR "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 09:36 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 31.31 (neutral) |
| vs SMA50 | Below (USD 0.64) |
| MACD | -0.06 (negative) |
From Sobr Safe, Inc.'s Latest SEC 10-K Filing (filed 2026-04-10)
Key Strengths & Strategy (as disclosed to the SEC)
- To protect our proprietary rights, we will rely on a combination of patent, copyright and trade secret laws, confidentiality agreements with our employees and third parties, and protective contractual provisions.
- Our ongoing focus will be placed on product innovation, providing data-driven user insights, and ensuring that new offerings remain consistent with our mission to promote a healthier, safer world free from the impacts of alcohol with balanced lifestyles.   Marketing   We have developed a marketing plan that includes:     Our marketing strategy continues to evolve as we expand our focus across business-to-business (B2B) and consumer markets.
- If our technology proves to be ineffective at tracking alcohol in an individual's system through perspiration from their skin, it would significantly impact our business.   We may not be able to meet our future capital needs.   To date, we have generated limited revenue.
- Any financing, if available, may be on unfavorable terms.   If we cannot obtain, achieve or sustain profitability or additional funding, our technology, product development and commercialization efforts may be reduced or discontinued, and we may not be able to continue operations.   We have experienced recurring net losses since inception, and as of December 31, 2025, had an accumulated deficit of $106,873,875.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VRAX | Virax Biolabs Group Limited | USD 2.63 | ▲ 3.14% |
| AKAN | Akanda Corp. | USD 3.35 | ▼ 10.43% |
| LUCY | Innovative Eyewear, Inc. | USD 0.93 | ▼ 1.18% |
| SKYA | SkyAI, Inc. | USD 1.38 | ▲ 8.66% |
| XPON | Expion Energy, Inc. | USD 5.86 | ▼ 3.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 09:36 UTC. This page is informational and not investment advice.